Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Die Folgen des Klimwandels haben einen direkten Einfluss auf die Primärversorgung in Deutschland: Hitzeschutz insbesondere bei älteren Patienten, die Zunahme von Infektionen und die Verlängerung der Allergiesesaison spielen medizinisch eine bedeutsame Rolle. Aber auch in der Prävention und der Aufklärung der Patienten kommt den Hausärztinnen und -ärzten eine besondere Rolle zu. Direkt aus der Praxis berichtet im Live-Webinar am 13. Mai von 18 bis 19 Uhr unser Experte Dr. med. Robin Maitra.
Erweiterte Suche
Anmelden
nach oben
CNS Drugs
Erschienen in: CNS Drugs 10/2001

01.10.2001 | Leading Article

Calcitonin Gene-Related Peptide (CGRP) and the Pathophysiology of Headache

Therapeutic Implications

verfasst von: Dr Lars Edvinsson

Erschienen in: CNS Drugs | Ausgabe 10/2001

Einloggen, um Zugang zu erhalten

Abstract

Cerebral blood vessels are innervated by sensory nerves that store several neurotransmitters. In primary headaches, there is a clear association between head pain and the release of the neuropeptide calcitonin gene-related peptide (CGRP). Furthermore, when triptan antimigraine agents are administered, headache subsides and the neuropeptide release normalises, in part via a presynaptic effect.
The central role of CGRP in primary headaches has led to the search for suitable antagonists of the receptors for this neuropeptide, which it is hoped will have less cardiovascular adverse effects than the triptans. Recently, the initial pharmacological profile of such a group of compounds has been disclosed. These compounds are small molecules with high selectivity for human CGRP receptors. Hypothetically, these agents will be efficacious in the relief of migraine headaches via blockade of the effects of CGRP.
Fußnoten
1
pA2 is the negative logarithm of the drug concentration causing a two-fold shift to the right of a dose-response curve.
 
Literatur
1.
Amara SG, Jonas V, Rosenfeld MG, et al. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 1982; 298: 240–2PubMedCrossRef
2.
Sexton PM. Central nervous binding sites for calcitonin and calcitoningene-related peptide. Mol Neurobiol 1991; 5: 251–73PubMedCrossRef
3.
Brain SD, Cambridge H. Calcitonin gene-related peptide: vasoactive effects and potential therapeutic role. Gen Pharmacol 1996; 27: 607–11PubMedCrossRef
4.
Uddman R, Edvinsson L, Ekblad E, et al. Calcitonin gene-related peptide (CGRP): perivascular distribution and vasodilatory effects. Regul Pept 1986; 15: 1–23PubMedCrossRef
5.
Poyner D, Marshall I, Brain SD. The CGRP family: calcitonin gene-related peptide (CGRP), amylin and adrenomedullin. Georgetown (TX): Landes Bioscience, 2000: 1–261
6.
Edvinsson L. Functional role of perivascular peptides in the control of the cerebral circulation. Trends Neurosci 1985; 8: 126–31CrossRef
7.
Uddman R, Edvinsson L, Ekman R, et al. Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. Neurosci Lett 1985; 62: 131–6PubMedCrossRef
8.
Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of man and the cat during activation of the trigeminovascular system. Ann Neurol 1988; 23: 193–6PubMedCrossRef
9.
Jansen-Olesen I, Mortensen A, Edvinsson L, et al. Calcitonin gene-related peptide is released from capsaicin-sensitive nerve fibres and induces vasodilation of human cerebral arteries concomitant with activation of adenylyl cyclase. Cephalalgia 1996; 16: 310–6PubMedCrossRef
10.
Edvinsson L, Jansen I, Kingman TA, et al. Cerebrovascular responses to capsaicin in vitro and in situ. Br J Pharmacol 1990; 100: 312–8PubMedCrossRef
11.
Edvinsson L. Aspects on the pathophysiology of migraine and cluster headache. Pharmacol Toxicol 2001; 88: 65–73CrossRef
12.
McCulloch J, Uddman R, Kingman TA, et al. Calcitonin gene-related peptide: functional role in cerebrovascular regulation. Proc Natl Acad Sci U S A 1986; 83: 5731–5PubMedCrossRef
13.
Edvinsson L, Ekman R, Jansen I, et al. Peptide-containing nerve fibers in human cerebral arteries: immunohistochemistry, radio-immunoassay and in vitro pharmacology. Ann Neurol 1987; 21: 431–7PubMedCrossRef
14.
Goadsby PJ. Inhibition of calcitonin gene-related peptide byh-CGRP8-37 antagonizes the cerebral dilator response fromnasociliary nerve stimulation in the cat. Neurosci Lett 1993; 151: 13–6PubMedCrossRef
15.
Gulbenkian S, Uddman R, Edvinsson L. Neuronal messengers in the human cerebral circulation. Peptides 2001; 22: 995–1007PubMedCrossRef
16.
Ray BS, Wolff HG. Experimental studies on headaches, pain sensitive structures of the head and their significance in headaches. Arch Surg 1940; 41: 813–56CrossRef
17.
Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990; 28: 183–7PubMedCrossRef
18.
Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993; 33: 48–56PubMedCrossRef
19.
Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain 1994; 117 Pt 3: 427–34
20.
Edvinsson L, Hara H, Uddman R. Retrograde tracing of nerve fibers to the rat middle cerebral artery with true blue: colocalization with different peptides. J Cereb Blood Flow Metab 1989; 9: 212–8PubMedCrossRef
21.
Gallai V, Sarchielle P, Floridi A, et al. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia 1995; 15: 384–90PubMed
22.
Fanciullacci M, Alessandri M, Figini M, et al. Increase in plasma calcitonin gene-related peptide from the extracerebral circulation during nitroglycerin-induced cluster headache attack. Pain 1995; 60: 119–23PubMedCrossRef
23.
Fanciullacci M, Alessandri M, Sicuteri R, et al. Responsiveness of the trigeminovascular system to nitroglycerine in cluster headache patients. Brain 1997; 120: 283–8PubMedCrossRef
24.
Goadsby PJ, Edvinsson L, Ekman R. Cutaneous sensory stimulation leading to facial flushing and release of calcitonin gene-related peptide. Cephalalgia 1992; 12: 53–6PubMedCrossRef
25.
Goadsby PJ, Edvinsson L. Neuropeptide changes in a case of chronic paroxysmal hemicrania: evidence for trigemino-parasympathetic activation. Cephalalgia 1996; 16: 448–50PubMedCrossRef
26.
Chiba T, Yamaguchi A, Yamatani T, et al. Calcitonin gene-related peptide receptor antagonist human CGRP(8-37). Am J Physiol 1989; 256(2 Pt 1): E331–5PubMed
27.
Dennis T, Fournier A, St Pierre S, et al. Structure-activity profile of calcitonin gene-related peptide in peripheral and brain tissues.Evidence of receptor multiplicity. J Pharmacol Exp Ther 1989; 251: 718–25PubMed
28.
Mimeault M, Fournier A, Dumont Y, et al. Comparative affinities and antagonistic potencies of various human calcitonin gene-related peptide fragments on calcitonin gene-related peptide receptors in brain and periphery. J Pharmacol Exp Ther 1991; 258: 1084–90PubMed
29.
Dennis T, Fournier A, Guard S, et al. Calcitonin gene-related peptide (hCGRP alpha) binding sites in the nucleus accumbens. Atypical structural requirements and marked phylogenic differences. Brain Res 1991; 539: 59–66PubMedCrossRef
30.
Waugh DJ, Bockman J, Smith CS, et al. Limitations in using peptide drugs to characterize calcitonin gene-related peptide receptors. J Pharmacol Exp Ther 1999; 289: 1419–26PubMed
31.
Aiyar N, Rand K, Elshourbagy NA, et al. A cDNA encoding the calcitonin gene-related peptide type I receptor. J Biol Chem 1996; 271: 11325–9PubMedCrossRef
32.
McLatchie LM, Fraser NJ, Main MJ, et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 1998; 393: 333–9PubMedCrossRef
33.
Foord SM, Marshall FH. RAMPs: accessory proteins for seven transmembrane domain receptors. Trends Pharmacol Sci 1999; 20: 184–7PubMedCrossRef
34.
Kuwasako K, Shimekake Y, Masuda M, et al. Visualization of the calcitonin receptor-like receptor and its receptor activity-modifying proteins during internalization and recycling. J Biol Chem 2000; 275: 29602–9PubMedCrossRef
35.
Armour SL, Foord S, Kenakin T, et al. Pharmacological characterization of receptor-activity-modifying proteins (RAMPs) and the human calcitonin receptor. J Pharmacol Toxicol Methods 1999; 42: 217–24PubMedCrossRef
36.
Christopolous G, Perry KJ, Morfis M, et al. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Mol Pharmacol 1999; 56: 235–42
37.
Luebke AE, Dahl GP, Roos BA, et al. Identification of a protein that confers calcitonin gene-related peptide responsiveness to oocytes by using a cystic fibrosis transmembrane conductance regulator assay. Proc Natl Acad Sci U S A 1996; 93: 3455–60PubMedCrossRef
38.
Evans BN, Rosenblatt MI, Mayer LO, et al. CGRP-RCP, a novel protein required for signal transduction at calcitonin gene-related peptide and adrenomedullin receptors. J Biol Chem 2000; 275: 31438–43PubMedCrossRef
39.
Edvinsson L, Goadsby PJ, Uddman R. Amylin: localization, effects on cerebral arteries and on local cerebral blood flow in the cat. Sci World 2001; 1: 168–80CrossRef
40.
Jansen-Olesen I, Kaarill L, Edvinsson L. Characterization of CGRP1 receptors in the guinea pig basilar artery. Eur J Pharmacol 2001; 414: 249–58PubMedCrossRef
41.
Edvinsson L, Cantera L, Jansen-Olesen I, et al. Expression of calcitonin gene-related peptide 1 receptor mRNA in human trigeminal ganglia and cerebral arteries. Neurosci Lett 1997; 229: 209–11PubMedCrossRef
42.
Tajti J, Uddman R, Möller S, et al. Messenger molecules and receptor mRNA in the human trigeminal ganglion. J Auton Nerv Syst 1999; 76: 176–83PubMedCrossRef
43.
Sams A, Jansen-Olesen I. Expression of calcitonin receptor-like receptor (CRLR) and receptor-activity-modifying proteins in human cranial arteries. Neurosci Lett 1998; 258: 41–4PubMedCrossRef
44.
Doods H, Hallermayer G, Wu D, et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 2000; 129(3): 420–3PubMedCrossRef
45.
Edvinsson L, Sams A, Jansen-Olesen I, et al. Characterization of the effects of a non-peptide CGRP receptor antagonist in SK-N-MC cells and isolated human cerebral arteries. Eur J Pharmacol 2001; 415: 39–44PubMedCrossRef
46.
Powell KJ, Ma W, Sutak M, et al. Blockade and reversal of spinal morphine tolerance by peptide and non-peptide calcitonin gene-related peptide receptor antagonists. Br J Pharmacol 2000; 131: 875–84PubMedCrossRef
47.
Wu D, Eberlein W, Rudolf K, et al. Characterisation of calcitonin gene-related peptide receptors in rat atrium and vas deferens:evidence for a [Cys(Et)2,7]hCGRP-preferring receptor. Eur J Pharmacol 2000; 400: 313–9PubMedCrossRef
48.
Aiyar N, Daines RA, Disa J, et al. Pharmacology of SB-273779, a nonpeptide calcitonin gene-related peptide 1 receptor antagonist. J Pharmacol Exp Ther 2001; 296: 768–75PubMed
49.
Hou M, Kanje M, Longmore J, et al. 5-HT1B and 5-HT1Dreceptors in the human trigeminal ganglion: co-localization with calcitonin gene-related peptide, substance P and nitric oxide synthase. Brain Res 2001; 909: 112–20PubMedCrossRef
Metadaten
Titel
Calcitonin Gene-Related Peptide (CGRP) and the Pathophysiology of Headache
Therapeutic Implications
verfasst von
Dr Lars Edvinsson
Publikationsdatum
01.10.2001
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 10/2001
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200115100-00001

Weitere Artikel der Ausgabe 10/2001

CNS Drugs 10/2001 Zur Ausgabe

Therapy in Practice

Sleep Disturbances in Patients with Alzheimer’s Disease

Therapy in Practice

Severe Depression

Current Opinion

Design of Clinical Trials of Antidepressants

Review Article

Role of Estrogen in the Aetiology and Treatment of Mood Disorders

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Vierten reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise